lunes, 16 de noviembre de 2026

Brazil after the vote: new challenges in health and science for the next 4 years The Lancet Regional Health – Americas (++...)

Brazil after the vote: new challenges in health and science for the next 4 years The Lancet Regional Health – Americas https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00343-1/fulltext?dgcid=raven_jbs_etoc_email Brazil is home to nearly a third of the people of Latin America and the Caribbean, so its health policy carries weight across the region. On Oct 25, 2026, Luiz Inácio Lula da Silva was re-elected president and on Jan 5, 2027, the left-wing leader begins an unprecedented fourth term with a mandate from a divided country. His third term sought to expand public health policies and a health system weakened by the COVID-19 pandemic and the previous administration's response. The next term should be assessed on whether these efforts will translate into better prevention, preparedness, and timely access to care. Health care in Brazil begins with the Unified Health System (Sistema Único de Saúde [SUS]). The SUS provides free universal care for approximately 214 million people. The principal health commitments in Lula's Government plan centre on expanding and strengthening the SUS through its main programmes: Mais Médicos (More Doctors), which places doctors in underserved areas; Agora Tem Especialistas (Now There Are Specialists), which expands specialist care, partly through private providers; and Farmácia Popular (People's Pharmacy), which supplies medicines for hypertension, diabetes, and other chronic conditions free of charge. By the Government's account, since 2023, Mais Médicos roughly doubled in size and coverage rose for 15 of the 16 main childhood vaccines. Moreover, the SUS performed a record number of elective surgeries in 2025. Sustaining this expansion will require stable financing and efficient spending. https://www.thelancet.com/journals/lanam/issue/vol63nonull/PIIS2667-193X(26)X2008-7

Oncology Cases & Quizzes: Gallstone-Related Abscess in a Man 11 Years After Surgery (+...)

Oncology Cases & Quizzes Gallstone-Related Abscess in a Man 11 Years After Surgery A 68-year-old man develops thoracic pain and recurrent fever 11 years after laparoscopic cholecystectomy; imaging reveals a perihepatic abscess linked to a gallstone. Medscape Europe, November 15, 2026 https://www.medscape.com/index/list_12039_0

Oncology News: EPH 2026 - Cancer Care Must Integrate Antimicrobial Stewardship (+...)

Oncology News EPH 2026 Cancer Care Must Integrate Antimicrobial Stewardship Speakers in Bilbao said oncology, infectious diseases, and intensive care teams must work together from the start of treatment. Medscape News Europe, November 16, 2026 https://www.medscape.com/index/list_13474_0

Most Read Papers - Cancer Science & Oncogenesis (+...)

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_261113

Midwifery and maternal health The Lancet Primary Care (++...)

Midwifery and maternal health The Lancet Primary Care https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00131-7/fulltext?dgcid=raven_jbs_etoc_email In 2023, approximately 260 000 women died due to pregnancy or childbirth. Although this is around a 40% decrease from 443 000 deaths in 2000, progress in improving maternal and neonatal outcomes is moving at such a pace that the likelihood of reaching Sustainable Development Goal (SDG) target 3·1 of reducing the global maternal mortality ratio to less than 70 maternal deaths per 100 000 livebirths by 2030 is dwindling fast. Without high-quality care and timely intervention when needed, pregnant women, birthing people, and their newborns can experience avoidable adverse outcomes, including long-term health problems, poor birth outcomes, health complications, and even death. https://www.thelancet.com/journals/lanprc/issue/vol2no10/PIIS3050-5143(26)X2010-6

Collaborative Excellence in Cancer Care: A Multidisciplinary Approach to Integrating Subcutaneous Immunotherapy Authors: Solange Peters, MD, PhD; Mauricio Burotto, MD; Jürgen E. Gschwend, MD, PhD

https://www.medscape.org/viewarticle/collaborative-excellence-cancer-care-multidisciplinary-2026a1000knq?page=1&src=mkmcmr_driv_stan_mscpedu_261116-OUS-HONC-collaborative-excellence-cancer-care-multidisciplinary-2026a1000knq-cta&uac=148436CN

FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration has approved Gazyva (obinutuzumab) injection to treat adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria (protein in the urine). This is the first drug approved specifically for the treatment of adults with primary membranous nephropathy.